Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 2, 2001, Pages

  Solal Celigny P ^a  

^a CENTRE JEAN BERNARD   (France)

Author keywords

Anti CD20 monoclonal antibody; bcl 2 Gene; Follicular non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; RITUXIMAB;

CANCER GRADING; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; LEUKEMIA REMISSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034958895     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
2. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituxlmab
3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
4. Monoclonal anti-CD20 antibody in mantle cell lymphoma and diffuse large B-cell lymphoma
5. Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumour: Clinical and molecular evaluation
6. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
7. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma
8. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
9. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
10. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy